Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study

The aim of this study was to validate the Hammersmith functional motor scale for children with spinal muscular atrophy in a large cohort of 90 non-ambulant children with spinal muscular atrophy type 2 or 3. All had a baseline assessment ( T0) and were reassessed either at 3 months ( T1) ( n=66) or a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuromuscular disorders : NMD 2006-02, Vol.16 (2), p.93-98
Hauptverfasser: Mercuri, E., Messina, S., Battini, R., Berardinelli, A., Boffi, P., Bono, R., Bruno, C., Carboni, N., Cini, C., Colitto, F., D'Amico, A., Minetti, C., Mirabella, M., Mongini, T., Morandi, L., Dlamini, N., Orcesi, S., Pelliccioni, M., Pane, M., Pini, A., Swan, A.V., Villanova, M., Vita, G., Main, M., Muntoni, F., Bertini, E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study was to validate the Hammersmith functional motor scale for children with spinal muscular atrophy in a large cohort of 90 non-ambulant children with spinal muscular atrophy type 2 or 3. All had a baseline assessment ( T0) and were reassessed either at 3 months ( T1) ( n=66) or at 6 months ( T2) ( n=24). Inter-observer reliability, tested on 13 children among 3 examiners, was >95%. Of the 66 children examined after 3 months 4 had adverse effects in between assessments and were excluded from the analysis. Forty-two (68%) of the remaining 62 reassessed had no variation in scores between T0 and T1 and 13 (21%) were within ±1 point. 9 (37.5%) of the 24 children reassessed after 6 months had no variation in scores between T0 and T2 and another 9 (37.5%) had variations within ±1 point. Our study confirms previous observations of the reliability of the scale and helps to establish a baseline for assessing changes of functional ability over 3 and 6 month intervals. This information can be valuable in view of therapeutic trials.
ISSN:0960-8966
1873-2364
DOI:10.1016/j.nmd.2005.11.010